Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Bad Krozingen – page 41

689 clinical trials in Bad Krozingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Krozingen at a glance
689
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

689 trials in Bad Krozingen

Open in trial search

Marginal zone lymphoma+3

Not recruiting

Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Universitaetsklinikum Ulm AöR

Rheumatoid arthritis

Not recruiting

Study on Spironolactone for Treating Active Rheumatoid Arthritis in Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Spironolactone
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Chronic graft versus host disease

Not recruiting

Study on Axatilimab and Ruxolitinib for Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Type 1 diabetes mellitus

Not recruiting

Study on the Effects and Safety of Ladarixin for Adults and Adolescents with Recent Onset Type 1 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Ladarixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Dilated cardiomyopathy

Not recruiting

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Prostate cancer

Not recruiting

Study on Hormonal Treatment with Leuprorelin Acetate for Prostate Cancer Patients at High Risk of Recurrence After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leuprorelin Acetate
  • Sponsor:Unicancer

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Dry age-related macular degeneration

Not recruiting

Study on Long-Term Safety and Effects of Pegcetacoplan for Patients with Geographic Atrophy from Age-Related Macular Degeneration

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Acute myeloid leukaemia+2

Not recruiting

Study on Continued Treatment with Sabatolimab for Adults with High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Unfit for Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Novartis Pharma AG

Granulomatosis with polyangiitis+1

Not recruiting

Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Systemic lupus erythematosus+3

Not recruiting

Study on the Effects of Ianalumab in Adults with Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Sjögren’s Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Bad Krozingen

What the registry says about research in the country

01 Cardiovascular Disease Management

Innovative research focusing on lipoprotein management and preventive therapies for cardiovascular disease, exploring new treatments to reduce major cardiovascular events in high-risk patients.

  • Cardiovascular death prevention
  • Stroke prevention
  • Myocardial infarction management

Advanced studies evaluating novel therapeutic approaches for better cardiovascular outcomes.

02 Thrombosis and Embolism

Clinical investigations into deep vein thrombosis treatments and prevention of systemic embolism, particularly in patients with atrial fibrillation.

  • Clot lysis therapy
  • Pulmonary embolism treatment
  • Anticoagulation strategies

Comprehensive research on blood clot prevention and treatment methodologies.

03 Cardiac Conditions

Studies addressing hypertension management and innovative treatments for acute coronary syndromes, including specialized interventions for heart attack prevention.

  • Blood pressure control
  • Acute myocardial infarction
  • Coronary interventions

Evaluating cutting-edge therapies for various cardiac conditions.

04 Vascular Health

Research focusing on peripheral arterial disease and advanced vascular interventions, including novel contrast medium strategies for better patient outcomes.

  • Peripheral vascular interventions
  • Kidney protection strategies
  • Vascular disease management

Developing safer and more effective vascular treatment approaches.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.